Giant cell arteritis: A multicenter observational study in Brazil

Clinics

Volumn 68, Issue 3, 2013, Pages 317-322

  de Souza, Alexandre Wagner Silva ^a   Kajiyama Okamoto, Karine Yoshiye ^a   Abrantes, Fabiano ^a   Schau, Bruno ^b   Santos Bacchiega, Ana Beatriz ^b   Shinjo, Samuel Katsuyuki ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Giant cell arteritis; Glucocorticoids; Methotrexate; Multicenter study; Vasculitis

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

AGED; ARTICLE; BIOPSY; BRAZIL; FEMALE; GIANT CELL ARTERITIS; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TEMPORAL ARTERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; BIOPSY; BRAZIL; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; STATISTICS, NONPARAMETRIC; TEMPORAL ARTERIES;

EID: 84878147880     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(03)OA06     Document Type: Article

References (33)

1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234-245.
2. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Eng J Med. 2002;347(4):261-271.
3. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012;11(6-7):A544-A554.
4. Gonzales-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454-1461.
5. Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculitis. Best Pract Res Clin Rheumatol. 2010;24(6):871-883.
6. Alba MA, Mena-Madrazo JA, Reyes E, Flores-Suarez LF. Giant cell arteritis in Mexican patients. J Clin Rheum. 2012;18(1):21-27.
7. dos Anjos DA, dos Anjos RF, de Paula WD, Sobrinho AB. F-18 FDG PET/ CT in giant cell arteritis with polymyalgia rheumatica. Clin Nucl Med. 2008;33(6):402-404.
8. Godoy P, Araujo S de A, Paulino E Jr, Lana-Peixoto MA. Coronary giant cell arteritis and acute myocardial infarction. Arq Bras Cardiol. 2007;88(4):e84-e87.
9. Monteiro ML. Anterior ischemic optic neuropathy: a comparison of the optic disc area of patients with the arteritic and non-arteritic forms of the disease and that of normal controls. Arq Bras Ophthalmol. 2006; 69(6):805-810.
10. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128.
11. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Pena-Segredo JL, Martin J, Gonzalez-Gay MA. Implication of the age in the clinical spectrum of giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S16-S22.
12. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum. 1981;24(7):899-904.
13. Narvaez J, Nolla-Solé JM, Valverde-García J, Roig-Escofet D. Sex differences in temporal arteritis and polymyalgia rheumatica. J Rheumatol. 2002;29(2):321-325.
14. Schuurs AH, Verheul HA. Effects of gender and sex steroids on the immune response. J Steroid Biochem. 1990;35(2):157-172.
15. Machado EB, Michet CJ, Ballard DJ, Hunder GG, Beard CM, Chu CP, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum. 1988;31(6):745-749.
16. Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca X. Influence of age, sex, and place of residence on clinical expression of giant cell arteritis in Northwest Spain. J Rheumatol. 2003;30(7):1548-1551.
17. Nir-Paz R, Gross A, Chajek-Shaul T. Sex differences in giant cell arteritis. J Rheumatol. 2002;29(6):1219-1223.
18. Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53(2):293-297.
19. González-Gay MA, García-Porruà C, Llorca J, Hajeer AH, Brañas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79(5):283-292.
20. Nesher G, Berkun Y, Mates M, Baras M, Nesher R, Rubinow A, et al. Risk factors for cranial complications of GCA. Medicine (Baltimore). 2004;83(2):114-122.
21. Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from Northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83(6):335-341.
22. Nuenninghof DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3522-3531.
23. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med. 1975;83(6):806-812.
24. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310-3318.
25. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernandez-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789-2797.
26. Martinez-Lado L, Calviño-Díaz C, Piñeiro A, Dierssen T, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90(3):186-193.
27. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703-708.
28. Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987;5(3):205-215.
29. Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scan. 1986;220(5):465-469.
30. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54(10):3306-3309.
31. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complication in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332-1337.
32. Narváez J, Bernad B, Gómez-Vaquero C, García-Gómez C, Roig-Vilaseca D, Juanola X. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57-62.
33. Prieto-González S, Arguis P, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Butjosa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71:1170-1176.